Eli Lilly has begun the week with ... Tirzepatide, the GLP-1 drug in Mounjaro and Zepbound, is Lilly’s highest-profile MASH candidate. Lilly reported phase 2 MASH data in June and later outlined ...

One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Eli Lilly’s profit doubled in the ... industry analysts by FactSet. Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as nausea, vomiting, and diarrhea. But, hair loss was not ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Eli Lilly & Co. tapped the US investment-grade bond ... Initial price talk was in the area of 1.15 percentage points over Treasuries.

a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and ...

Eli Lilly is just weeks away from ... a four-dose version of the drug, called Mounjaro KwikPen, which provides a month’s course of GLP-1 and GIP agonist tirzepatide. Great Britain will be ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Since the approval of human insulin (Humulin) in 1982, the FDA has approved 59 unique antidiabetic drugs, including 36 new molecular entities and 23 drug combinations.’ The paper is one of ...